Salute e Benessere

Novo Holdings participates in $290m strategic financing of Sangon Biotech

With 47 manufacturing facilities across China, and a customer base comprising more than 7,000 academic institutions and over 40,000 biotech/biopharma and IVD companies across the country, Sangon ranges as the number one provider of DNA synthesis in China. Overall, the Company is among the leading life science tool providers in China, where the life science tool market segment continues to grow by 15% annually, excluding the effects of COVID-19. With 47 manufacturing facilities acrossChina,...
PR Newswire
17/08/2023

TraceLink Collaborates with GS1 US to Author GS1 US Addendum Guidance and XML…

The latest implementation documents, published by GS1 US on May 26th, 2023, serve as an EPCIS serialized data exchange implementation blueprint for companies across the US pharmaceutical and healthcare supply chain. The expanded documentation provides detailed descriptions of end-to-end trading partner event choreographies for serialized item traceability use cases under DSCSA. The latest implementation documents, published by GS1 US onMay 26th, 2023, serve as an EPCIS serialized data...
PR Newswire
17/08/2023

Cough-assisted Devices Global Market to Register Incremental Growth at a CAGR of…

Key Takeaways from the Cough-assisted Devices Market Report Key Takeaways from the Cough-assisted Devices Market Report To read more about the latest highlights related to the cough-assisted devices market, get a snapshot of the key highlights entailed in theGlobal Cough-assisted Devices Market Report Cough-assisted Devices Overview Cough-assisted devices are innovative medical tools designed to aid individuals with impaired cough function, often seen in conditions such as...
PR Newswire
16/08/2023

US FDA approves Ipsen's SohonosTM (palovarotene) capsules, the first and only…

Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)FOP impacts about 400 people in the U.S., it leads to progressive mobility loss, severely limits quality of life and shortens median life expectancy to 56 yearsSohonos TMmay be prescribed immediately in the U.S. for eligible patients, aged 8 years and older for females and 10 years and older for males...
Nasdaq GlobeNewswire
16/08/2023

Heart Failure start-up, Acorai, embarks on the next vital stage towards…

The first of the patients in the Acorai MLG Study (Machine Learning Generalisation) [NCT05835024] was enrolled at Royal Brompton and Harefield Hospitals by Dr. Owais Dar and his team. Dr. Dar is a cardiologist specializing in heart failure and leads the advanced heart failure, heart transplant, and mechanical circulatory support research programme at Harefield Hospital. Dr. Dar said, "This is a fantastic achievement after over a year of planning to get to the stage of final testing of the…
PR Newswire
16/08/2023

GN Store Nord delivered strong organic growth in GN Hearing and solid sequential…

- - GN Store Nord GN executed strongly across the company despite continued challenging market conditions in GN Audio. GN increased revenue by 4% compared to Q1 2023, equal to an organic revenue growth of -8% due to a high comparison base from last yearAdj. EBITA was DKK 404 million, equal to an adj. EBITA margin improvement of 3.2 percentage points compared to Q1 2023 (decline of 3.4 percentage points compared to Q2 2022)Due to a relentless focus on balance sheet items, free cash flow...
Nasdaq GlobeNewswire
16/08/2023

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Regulated InformationLeuven, BELGIUM, Boston, MA, US – August16 , 2023 – 7 .00PM CETOxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on August 15,...
Nasdaq GlobeNewswire
16/08/2023

Update of financial guidance for 2023

Following a stronger than expected Q2 2023 and continued strong sales momentum, GN Hearing is upgrading its organic revenue growth guidance from “5% to 10%” to “9% to 13%”. The EBITA margin in the core business of “14% to 16%” is confirmed to allow for further investments to drive growth, as well as preserving flexibility to take appropriate actions to ensure continued margin expansion.Following a slower than expected market recovery in GN Audio's Enterprise business, GN Audio's organic...
Nasdaq GlobeNewswire
16/08/2023

The opportunity within the global antibiotics market is projected to grow at a…

Clinical trials have demonstrated the enormous benefits offered by novel antibiotics for the treatment of a wide range of infections, presenting lucrative opportunities for the players engaged in the development of these therapies. Driven by the extensive R&D efforts of both industry and non-industry players, along with the growing demand for effective antibiotic therapies, the market is anticipated to witness steady growth over the next decade. Clinical trials have demonstrated the…
PR Newswire
16/08/2023

COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined…

Transaction led by healthcare specialist investors, TCGX and Aisling Capital$125 million financing upfront with up to an additional $160 million tied to exercise of warrantsNet proceeds from financing expected to extend cash runway into late 2025LONDON, Aug.16, 2023(GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has entered into...
Nasdaq GlobeNewswire
16/08/2023

Department of Health - Abu Dhabi, the UAE's healthcare regulator announces…

Reflecting the UAE capital's position as a leading global hub for healthcare, the event aims to provide a platform to foster dialogue, share knowledge, and drive investment - focused on healthcare for all. Centred on four key pillars, including reimagining healthcare, diverse and inclusive health, trailblazing medical breakthroughs and disruptive healthcare, the conference will provide a forum for the fields of genomics, digital and mental health, biotech, pharmaceuticals, research, innovation…
PR Newswire
16/08/2023

Vistin Pharma ASA: Invitation to Q2 2023 conference call

Vistin Pharma ASA will release its second quarter and YTD 2023 results on Wednesday 23 rdof August 2023. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Wednesday 23 rdof August at 08:30 CET. There will be a Q&A session following the management discussion.The conference call will be held in English.The second quarter conference call will be available via web and audio through the following access points: Webcast:...
Nasdaq GlobeNewswire
16/08/2023

IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2023

Aggregatedpresentationbydayandbymarket Name of issuerIdentificationcodeof issuer (Legal Entity Identifier)Day of transactionIdentificationcodeof financial instrumentAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares *Market (MIC Code) IPSEN549300M6SGDPB4Z94P1107/08/2023FR001025915040115.70CEUXIPSEN549300M6SGDPB4Z94P1107/08/2023FR00102591501,560115...
Nasdaq GlobeNewswire
16/08/2023

New and Updated Resources Published to Help Guide Oncology Care in the Middle…

View the new and updated International Adaptations of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) MENA Editions at NCCN.org/global. View the new and updated International Adaptations of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) MENA Editions atNCCN.org/global. The NCCN Guidelines ®MENA Editions now include up-to-date adaptations for: The guidelines provide color-coded information for health care providers on how to care for people with...
PR Newswire
16/08/2023

MedAlliance announces the completion of enrollment in SAVE Trial with SELUTION…

"We very much look forward to the analysis of the primary endpoint of this important trial at six months, as this is the first prospective randomized trial of a sirolimus-coated balloon in AVF patients with angiographic follow up. Furthermore, we have also measured fistula volume flow rates, which is another key index of failing or maintained fistula function. I thank MedAlliance for initiating a trial in this difficult patient population" commented Principal Investigator (PI) Dr…
PR Newswire
16/08/2023

Tetra Pharm Technologies inaugurates new R&D, manufacturing and production…

Former manufacturing site of medical solutions company Ambu A/S, the facility has undergone extensive construction and building upgrades to accommodate the specific needs of Tetra Pharm Technologies to enlarge its manufacturing capacity, bolster and streamline its production capabilities, and provide an optimal environment for the company's ambitious R&D activities. Former manufacturing site of medical solutions company Ambu A/S, the facility has undergone extensive construction and…
PR Newswire
16/08/2023

Sectra signs enterprise imaging contract with one of the larger multi-region…

"Health systems are under tremendous pressure to maintain patient excellence while balancing growing financial and staffing concerns," shared Isaac Zaworski, the President of Sectra, Inc. "Regardless of size or infrastructure challenges, Sectra is focused on driving down the costs and complexity of traditional on-premise solutions with highly scalable, high-performance enterprise imaging solutions as a service. We are thrilled for the opportunity to help this health leader execute…
PR Newswire
16/08/2023

Bioretec unveils its revitalized Scientific Advisory Board (SAB), focusing on…

Bioretec is poised to transform orthopedic surgical practice with its new cutting-edge technology. The RemeOs™ product line represents a major milestone, offering a breakthrough solution that combines the benefits of biodegradability, implant strength, and performance. This transforming technology not only ensures effective treatment but also eliminates the need for subsequent implant removal surgeries, thereby enhancing patient comfort and reducing healthcare costs. Bioretec is poised to...
PR Newswire
16/08/2023

Mendus publishes preclinical data demonstrating synergies of ilixadencel and…

INTRATUMORAL PRIMING BOOSTED THE THERAPEUTIC EFFICACY OF ANTI-4-1BB ANTIBODY TREATMENT AND RESULTED IN A MORE TREATMENT-SUPPORTIVE TME Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced the publication of novel preclinical data on its intratumoral priming strategy in the peer-reviewed medical journal 'Frontiers in Immunology'. The data demonstrate the potential of proinflammatory allogeneic dendritic...
Nasdaq GlobeNewswire
16/08/2023

Ultimovacs ASA: Invitation to second quarter 2023 results webcast presentation

Oslo, 16August2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines , invites to a webcast presentation of its second quarter 2023 results on Tuesday22August2023 . The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 14:00 CET on Tuesday 22 August 2023, and is scheduled to conclude at 14:55 CET. The webcast presentation will be available...
Nasdaq GlobeNewswire
16/08/2023

AMFRESH Group and EQT Future Successfully Complete 100% Acquisition of IFG and…

In a world that increasingly demands healthier, more informed food choices, BLOOM is poised to revolutionize the landscape of fresh produce with innovation and expertise that respond to this evolving consumer paradigm. The combined strength and heritage of both companies, now under the BLOOM banner, will accelerate traditional fruit varietal breeding to create an unprecedented dynamic agri-tech platform driving advancements in taste, nutrition, sustainability, and global accessibility...
Nasdaq GlobeNewswire
16/08/2023

Daewoong Pharmaceutical Initiates Global Export of 'Novel Drug' Launching…

This release marks the first successful global expansion for Daewoong Pharmaceutical within just one year since the initial release of Fexuprazan. Developed independently with Daewoong Pharmaceutical's proprietary technology for 13 years since 2008, Fexuprazan is a pure domestic novel drug with five key strengths, including rapid onset of action, quick and significant symptom improvement, excellent nighttime symptom relief, convenience of administration, low drug interactions and consistency of…
PR Newswire
16/08/2023

Intravascular Ultrasound Global Market to Witness Upsurge in Growth at a CAGR of…

Key Takeaways from the Intravascular Ultrasound Market Report Key Takeaways from the Intravascular Ultrasound Market Report To read more about the latest highlights related to the intravascular ultrasound market, get a snapshot of the key highlights entailed in theGlobal Intravascular Ultrasound Market Report Intravascular Ultrasound Overview Intravascular Ultrasound (IVUS) is a cutting-edge medical imaging technique that plays a crucial role in the field of cardiology...
PR Newswire
15/08/2023

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement…

PARIS and CAMBRIDGE, Mass., Aug.15, 2023(GLOBE NEWSWIRE) -- NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the ''Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 for its previously announced (July 10, 2023) global licensing, co-development, and commercialization...
Nasdaq GlobeNewswire
15/08/2023
Altri  Comunicati